Online Only Articles

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain
Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain
Hematology Department. Clínica Universidad de Navarra, Spain
Clinical Department of Pathology, Clínica Universidad de Navarra, Spain
Center for Applied Medical Research (CIMA), University of Navarra, Spain;Clinical Immunology Department, Clínica Universidad de Navarra, Spain
Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;Centro de Investigación Biomédica en Red, Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Merck Sharp and Dohme Laboratories, New York City, NY, USA
Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;CIMALab Diagnostics, University of Navarra, Spain
Clinical Department of Pathology, Clínica Universidad de Navarra, Spain
Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;Centro de Investigación Biomédica en Red, Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
Vol. 103 No. 7 (2018): July, 2018 https://doi.org/10.3324/haematol.2017.185777